// App-Quantinova.ai

POS0579 (2022) : ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDY

Researchers

Presenter

  • P. Emery

Principal Investigators

  • R. Fleischmann

  • R. Wong

  • K. Lozenski

  • Y. Tanaka

  • V. Bykerk

  • C. Bingham

  • T. Huizinga

  • G. Citera

  • Y. Elbez

  • V. Perera

  • B. Murthy

  • K. Maxwell

  • J. Passarell

  • W. Hedrich

  • D. Williams

Medical Centers

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds Biomedical Research Centre, Leeds, United Kingdom

  • University of Texas, Division of Rheumatology, Dallas, United States of America

  • Bristol Myers Squibb, Medical Immunology, Princeton, United States of America

  • Bristol Myers Squibb, Medical Immunology, Princeton, United States of America

  • University of Occupational and Environmental Health, Japan, The second department on internal medicine, Kitakyusyu, Japan

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Johns Hopkins University, Divisions of Rheumatology and Allergy, Department of Medicine, Baltimore, United States of America

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

  • Instituto de Rehabilitación Psicofísica, Department of Rheumatology, Buenos Aires, Argentina

  • Signifience, Biostatistics, Paris, France

  • Bristol Myers Squibb, Clinical Pharmacology and Pharmacometrics, Princeton, United States of America

  • Cognigen Corporation, a Simulations Plus company, Pharmacometrics, Buffalo, United States of America

  • Cognigen Corporation, a Simulations Plus company, Pharmacometrics, Buffalo, United States of America

Locations

  • United Kingdom

  • United States

  • Japan

  • Netherlands

  • Argentina

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved